There aren't many ASX biotech stocks in Phase 3, and even fewer with successful interim data, but Dimerix (ASX:DXB) is one such company. Although it has some way to go in the trial, results released last month were encouraging and bode well for its eventual commercialisation. The company's shares have re-rated since the results, yet…
